AMA Adds Two CPT Codes Related to COVID-19
One code covers additional supplies and clinical time related to safety protocols. The other covers antibody testing.
The American Medical Association published two new COVID-19- related Current Procedural Terminology (CPT) codes today.
One addition, CPT code 99072, covers the additional supplies, materials and clinical staff time needed to perform safety protocols “during a public health emergency as defined by law due to respiratory-transmitted infectious disease.”
The other one, CPT code 86413, was approved in response to the development of laboratory tests that provide quantitative measurements of antibodies to SARS-CoV-2, the virus that causes COVID-19. “By measuring antibodies to SARS-CoV-2, the tests reported by 86413 can investigate a person’s adaptive immune response to the virus and help access the effectiveness of treatments used against the infection,” said a press release issued by the AMA this afternoon.
CPT codes are essential to claims processing; providers use them to bill payers for their services.
Descriptors of these two new codes and others related to COVID-19 can be found on the AMA website.
Changes to the CPT code set are considered through an editorial process managed by the AMA’s CPT Editorial Panel.
“The CPT code set continues to quickly adapt during the COVID-19 pandemic to streamline the reporting of innovative tools and services now available to help reduce the COVID-19 disease burden, improve health outcomes and reduce long-term care costs,” said AMA President Susan R. Bailey, M.D., in the press release.
Unrealistic Portrayals of Cardiac Arrest in Contemporary Film | ACC 2025
March 31st 2025Cardiac arrests in contemporary film are largely inaccurate when it comes to survival rate and etiology, according to a poster presented today at the American College of Cardiology conference held March 29 to 31 in Chicago.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Winrevair Reduced Risk of Morbidity and Mortality by 76% in PAH | ACC 2025
March 31st 2025In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension.
Read More
Clopidogrel Beat Aspirin in Preventing Heart Attacks After PCI | ACC 2025
March 31st 2025Clopidogrel monotherapy may be an alternative to aspirin for prevention of cardiac events in high-risk patients after percutaneous coronary intervention, according to a new study presented at ACC 2025.
Read More
